// App-Quantinova.ai

214 : Health-Related Quality of Life with CC-486 in Patients with Acute Myeloid Leukemia (AML) in First Remission Following Induction Chemotherapy (IC): Results from the Phase III QUAZAR AML-001 Maintenance Trial

Researchers

Presenter

  • Gail J. Roboz

Principal Investigators

  • Christopher Pocock

  • Herv Dombret

  • Farhad Ravandi

  • Jun Ho Jang

  • Dominik Selleslag

  • Jir Mayer

  • Uwe M. Martens

  • Jane L. Liesveld

  • Teresa Bernal del Castillo

  • Ming-Chung Wang

  • Ignazia La Torre

  • Barry Skikne

  • Keshava Kumar

  • Qian Dong

  • Julia Braverman

  • Salem Abi Nehme

  • C.L. Beach

  • Andrew H Wei

Medical Centers

  • Weill Medical College of Cornell University and the New York Presbyterian Hospital, New York, NY

  • University of Ulm, Ulm, Germany

  • Kent & Canterbury Hospital, Kent, United Kingdom

  • Institut de Recherche Saint-Louis, Université de Paris,Paris,France

  • Hopital Saint-Louis, Assistance Publique - Hopitaux De Paris (AP-HP), Paris, FRA

  • Department of Bioinformatics, The University of Texas MD Anderson Cancer Center, Houston, TX

  • Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic of (South)

  • AZ Sint-Jan Brugge-Oostende, Brugge, Belgium

  • University Hospital Brno, Brno, Czech Republic

  • Clinics Heilbronn , MOLIT Institute for personalized Medicine,Heilbronn,Germany

  • Wilmot Cancer Institute, University of Rochester, Rochester, NY

  • Hospital Universitario Central de Asturias, Oviedo, Spain

  • Division of Hematology-Oncology, Chang Gung Memorial Hospital, Taoyuan, Taiwan

  • Celgene International Sàrl, a Bristol Myers Squibb Company, Boudry, Switzerland

  • Kansas University Medical Center, Kansas City, KS

  • Bristol-Myers Sqiubb, Princeton, NJ

  • The Alfred Hospital, Melbourne, Australia

  • Australian Centre For Blood Diseases, Monash University, Melbourne, Australia

Locations

  • United States

  • Germany

  • United Kingdom

  • France

  • Republic of South Korea

  • Belgium

  • Czech Republic

  • Spain

  • Taiwan

  • Switzerland

  • Australia

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute myelocytic leukemia

Biomarkers

  • N/A

Drug/Treatment

  • CC-486

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Non Inferiority

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved